

FORM PTO-1390  
(REV 10-95)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

**TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. §371**

LOM 24

U.S. APPLICATION NO. (If known, see 37 CFR §1.5)

**09/936563**

INTERNATIONAL APPLICATION NO.

INTERNATIONAL FILING DATE

PCT/FR00/00608

14 MARCH 2000

PRIORITY DATE CLAIMED

15 MARCH 1999

TITLE OF INVENTION



METHOD FOR REDUCING FLUORESCENCE QUENCHING IN BIOASSAYS

APPLICANT(S) FOR DO/EO/US

MATHIS, Gérard, et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. §371.
  2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. §371.
  3. ☐ This express request to begin national examination procedures (35 U.S.C. §371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. §371(b) and PCT Articles 22 and 39(1).
  4. ☒ A proper Demand for International Preliminary Examination was made by the 19<sup>th</sup> month from the earliest claimed priority date.
  5. ☒ A copy of the International Application as filed (35 U.S.C. §371(c)(2))
    - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
    - b. ☒ has been transmitted by the International Bureau.
    - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
  6. ☒ A translation of the International Application into English (35 U.S.C. §371(c)(2)).
  7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. §371(c)(3))
    - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
    - b. ☐ have been transmitted by the International Bureau.
    - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
    - d. ☒ have not been made and will not be made.
  8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. §371(c)(3)).
  9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. §371(c)(4)).
  10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. §371(c)(5)).
- Items 11. to 16. below concern document(s) or information included:**
11. ☐ An Information Disclosure Statement under 37 C.F.R. §§1.97 and 1.98.
  12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. §§3.28 and 3.31 is included.
  13. ☒ A **FIRST** preliminary amendment.
  14. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
  15. ☐ A substitute specification.
  16. ☐ A change of power of attorney and/or address letter.
  17. ☐ Other items or information:

U.S. APPLICATION NO. (if known, see 37 CFR §1.5) <b>09/936563</b>		INTERNATIONAL APPLICATION NO. PCT/FR00/00608		ATTORNEY'S DOCKET NUMBER LOM 24	
17. <input checked="" type="checkbox"/> The following fees are submitted: <b>BASIC NATIONAL FEE (37 CFR §1.492 (a) (1) - (5)):</b> Search Report has been prepared by the EPO or JPO..... \$860.00 International preliminary examination fee paid to USPTO (37 CFR §1.482)..... \$690.00 No international preliminary examination fee paid to USPTO (37 CFR §1.482) but international search fee paid to USPTO (37 CFR §1.445(a)(2))..... \$710.00 Neither international preliminary examination fee (37 CFR §1.482) nor international search fee (37 CFR §1.445(a)(2)) paid to USPTO..... \$1000.00 International preliminary examination fee paid to USPTO (37 CFR §1.482) and all claims satisfied provisions of PCT Article 33(2)-(4)..... \$100.00				<b>CALCULATIONS</b> PTO USE ONLY	
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>				<b>\$860.00</b>	
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 C.F.R. §1.492(e)). <input type="checkbox"/> 20 <input type="checkbox"/> 30					
<b>CLAIMS</b>	<b>NUMBER FILED</b>	<b>NUMBER EXTRA</b>	<b>RATE</b>		
Total claims	19 - 20 =	0	x \$ 18.00	\$0.00	
Independent claims	1 - 3 =	0	x \$ 80.00	\$0.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$ 270.00		
<b>TOTAL OF ABOVE CALCULATIONS =</b>				<b>\$860.00</b>	
Reduction of 1/2 for filing by small entity, if applicable. A Verified Small Entity Statement must also be filed (Note 37 C.F.R. §§1.9, 1.27, 1.28).					
<b>SUBTOTAL =</b>				<b>\$860.00</b>	
Processing fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 C.F.R. §1.492(f)). <input type="checkbox"/> 20 <input type="checkbox"/> 30					
<b>TOTAL NATIONAL FEE =</b>				<b>\$860.00</b>	
Fee for recording the enclosed assignment (37 C.F.R. §1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 C.F.R. §§3.28, 3.31). \$40.00 per copy.					
<b>TOTAL FEES ENCLOSED =</b>				<b>\$860.00</b>	
				Amount to be refunded:	
				charged:	
a. <input checked="" type="checkbox"/> A check in the amount of <u>\$860.00</u> to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. <u>13-3402</u> in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>13-3402</u> . A duplicate copy of this sheet is enclosed.					
<b>NOTE: Where an appropriate time limit under 37 C.F.R. §§1.494 or 1.495 has not been met, a petition to revive (37 C.F.R. §1.137(a) or (b)) must be filed and granted to restore the application to pending status.</b>					
SEND ALL CORRESPONDENCE TO: Customer Number 23,599					
 <b>23599</b> PATENT TRADEMARK OFFICE			 SIGNATURE		
			<b>Harry B. Shubin</b> NAME		
Filed: 14 SEPTEMBER 2001			<b>32,004</b> REGISTRATION NUMBER		
HBS:kmo					

IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

International Application No. : PCT/FR00/00608  
International Filing Date : 14 MARCH 2000  
Priority Date(s) Claimed : 15 MARCH 1999  
Applicant(s) (DO/EO/US) : MATHIS, Gerard, et al.  
Title: METHOD FOR REDUCING FLUORESCENCE QUENCHING IN BIOASSAYS

PRELIMINARY AMENDMENT

Commissioner for Patents  
Washington, D.C. 20231

SIR:


Prior to calculating the national fee, and prior to examination in the National Phase of the above-identified International application, please amend as follows:

IN THE CLAIMS:

5. (Amended) The process as claimed in claim 1, characterized in that the oligonucleotide consists of ribonucleotide or deoxyribonucleotide units, one of which may comprise a functional group introduced onto or generated on said unit, or the functional group introduced using a spacer arm bonded to the terminal phosphate group in the 3' or 5' position.
7. (Amended) The process as claimed in claim 1, characterized in that the oligonucleotide comprises a chain of 5 to 50 nucleotides or a chain of 5 to 50 nucleotides and nucleotide or nucleoside analogs.
8. (Amended) The process as claimed in claim 1, characterized in that the oligonucleotide consists of a chain of ribonucleotide or deoxyribonucleotide units bonded to one another via phosphodiester-type bonds and of analogous units of nucleosides bonded to one another via amide bonds, said oligonucleotide comprising at least 5 phosphodiester-type internucleotide bonds at the end intended to be bonded to the cryptate.


9. (Amended) The process as claimed in claim 1, characterized in that the rare-earth metal cryptate is bonded covalently to the oligonucleotide either directly or via a spacer arm.


10. (Amended) The process as claimed in claim 1, characterized in that said rare-earth metal cryptate consists of at least one rare-earth metal salt complexed with a macropolycyclic compound of formula



in which Z is an atom with 3 or 4 valencies, R is nothing or represents hydrogen, a hydroxy group, an amino group or a hydrocarbon-based radical, the divalent radicals (A), (B) and (C) are, independently of each other, hydrocarbon-based chains which optionally contain one or more hetero atoms and are optionally interrupted with a hetero macrocycle, at least one of the radicals (A), (B) and (C), also comprising at least one molecular unit or consisting essentially of a molecular unit, said molecular unit having a triplet energy which is greater than that of the emission level of the complexed rare-earth metal ion.

12. (Amended) The process according to claim 1, characterized in that the rare-earth metal cryptate consists of at least one rare-earth metal salt complexed with a macropolycyclic compound corresponding to one of the formulae II or III below:








III

in which:

- the ring of formula



is one of the following rings:



0936563.091401

-Y is a spacer group or spacer arm which consists of a divalent organic radical, chosen from linear or branched C<sub>1</sub> or C<sub>20</sub> alkylene groups optionally containing one or more double bonds and/or optionally containing one or more hetero atoms such as oxygen, nitrogen, sulfur or phosphorus or one or more carbamoyl or carboxamido group(s); chosen from C<sub>5</sub> to C<sub>8</sub> cycloalkylene groups or chosen from C<sub>6</sub> to C<sub>14</sub> arylene groups, said alkylene, cycloalkylene or arylene groups being optionally substituted with alkyl, aryl or sulfonate groups;

-Z is a functional group capable of bonding covalently to a biological substance;

-R is a methyl group or represents the group -Y-Z;

-R' is hydrogen or a group -COOR'' in which R'' is a C<sub>1</sub> to C<sub>10</sub> alkyl group and preferably represents a methyl, ethyl or tert-butyl group, or alternatively R' is a group -CO-NH-Y-Z.

13. (Amended) The process as claimed in claim 1, characterized in that the rare-earth metal cryptate is bonded to the oligonucleotide via a spacer arm consisting of a divalent organic radical chosen from C<sub>1</sub>-C<sub>20</sub> linear or branched alkylene groups optionally containing one or more double bonds or triple bonds and/or optionally containing one or more hetero atoms, such as oxygen, nitrogen, sulfur, phosphorus or one or more carbamoyl or carboxamino group(s); C<sub>5</sub>-C<sub>8</sub> cycloalkylene groups and C<sub>6</sub>-C<sub>14</sub> arylene groups, said alkylene, cycloalkylene or arylene groups being optionally substituted with alkyl, aryl or sulfonate groups.

15. (Amended) The method as claimed in claim 1, characterized in that the rare-earth metal cryptate is a europium cryptate.

17. (Amended) The process as claimed in claim 1, characterized in that the fluorescent conjugate is used as the only label or as one of the fluorescent labels in the assay.

18. (Amended) The process as claimed in claim 1, characterized in that the fluorescent conjugate is bonded covalently to one of the members of a pair of molecules capable of binding specifically to one another, in particular a cellular receptor, an antigen, an antibody or a nucleic acid.

19. (Amended) The process as claimed in claim 1, characterized in that, in addition to said fluorescent conjugate, a fluorescent label comprising an acceptor fluorescent compound in the assay.


0935552.091401

REMARKS

The purpose of this Preliminary Amendment is to eliminate multiple dependent claims in order to avoid the additional fee. Applicants reserve the right to reintroduce claims to canceled combined subject matter.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached pages are captioned "**Version With Markings to Show Changes Made**".

Respectfully submitted,



Harry B. Shubin, Reg. No. 32,004  
Attorney for Applicants  
MILLEN, WHITE, ZELANO & BRANIGAN, P.C.  
Arlington Courthouse Plaza 1  
2200 Clarendon Boulevard, Suite 1400  
Arlington, VA 22201  
Direct Dial: 703-812-5306  
Facsimile: 703-243-6410  
Email: [shubin@mwzb.com](mailto:shubin@mwzb.com)

AJZ(HBS):jmm



VERSION WITH MARKINGS TO SHOW CHANGES MADE

Claims 5, 7, 8-10, 12-13, 15 and 17-19 have been amended as follows:


5. (Amended) The process as claimed in ~~any one of~~ claims 1 to 4, characterized in that the oligonucleotide consists of ribonucleotide or deoxyribonucleotide units, one of which may comprise a functional group introduced onto or generated on said unit, or the functional group introduced using a spacer arm bonded to the terminal phosphate group in the 3' or 5' position.

7. (Amended) The process as claimed in ~~any one of~~ claims 1 to 6, characterized in that the oligonucleotide comprises a chain of 5 to 50 nucleotides or a chain of 5 to 50 nucleotides and nucleotide or nucleoside analogs.

8. (Amended) The process as claimed in ~~any one of~~ claims 1 to 6, characterized in that the oligonucleotide consists of a chain of ribonucleotide or deoxyribonucleotide units bonded to one another via phosphodiester-type bonds and of analogous units of nucleosides bonded to one another via amide bonds, said oligonucleotide comprising at least 5 phosphodiester-type internucleotide bonds at the end intended to be bonded to the cryptate.



9. (Amended) The process as claimed in ~~any one of~~ claims 1 to 8, characterized in that the rare-earth metal cryptate is bonded covalently to the oligonucleotide either directly or via a spacer arm.

10. (Amended) The process as claimed in ~~any one of~~ claims 1 to 9, characterized in that said rare-earth metal cryptate consists of at least one rare-earth metal salt complexed with a macropolycyclic compound of formula




in which Z is an atom with 3 or 4 valencies, R is nothing or represents hydrogen, a hydroxy group, an amino group or a hydrocarbon-based radical, the divalent radicals (A), (B) and (C) are, independently of each other, hydrocarbon-based chains which optionally contain one or more hetero atoms and are optionally interrupted with a hetero macrocycle, at least one of the radicals (A), (B) and (C), also comprising at least one molecular unit or consisting essentially of a molecular unit, said molecular unit having a triplet energy which is greater than that of the emission level of the complexed rare-earth metal ion.

12. (Amended) The process according to any one of claims 1 to 9, characterized in that the rare-earth metal cryptate consists of at least one rare-earth metal salt complexed with a macropolycyclic compound corresponding to one of the formulae II or III below:





in which:

- the ring of formula



is one of the following rings:



-Y is a spacer group or spacer arm which consists of a divalent organic radical, chosen from linear or branched  $C_1$  or  $C_{20}$  alkylene groups optionally containing one or more double bonds and/or optionally containing one or more hetero atoms such as oxygen, nitrogen, sulfur or phosphorus or one or more carbamoyl or carboxamido group(s); chosen from  $C_5$  to  $C_8$  cycloalkylene groups or chosen from  $C_6$  to  $C_{14}$  arylene groups, said alkylene, cycloalkylene or arylene groups being optionally substituted with alkyl, aryl or sulfonate groups;

-Z is a functional group capable of bonding covalently to a biological substance;  
-R is a methyl group or represents the group -Y-Z;  
-R' is hydrogen or a group -COOR'' in which R'' is a C<sub>1</sub> to C<sub>10</sub> alkyl group and preferably represents a methyl, ethyl or tert-butyl group, or alternatively R' is a group -CO-NH-Y-Z.

13. (Amended) The process as claimed in ~~any one of claims 1 to 12~~, characterized in that the rare-earth metal cryptate is bonded to the oligonucleotide via a spacer arm consisting of a divalent organic radical chosen from C<sub>1</sub>-C<sub>20</sub> linear or branched alkylene groups optionally containing one or more double bonds or triple bonds and/or optionally containing or more hetero atoms, such as oxygen, nitrogen, sulfur, phosphorus or one or more cabamoyl or carboxamino group(s); C<sub>5</sub>-C<sub>8</sub> cycloalkylene groups and C<sub>6</sub>-C<sub>14</sub> arylene groups, said alkylene, cycloalkylene or arylene groups being optionally substituted with alkyl, aryl or sulfonate groups.

15. (Amended) The method as claimed in ~~any one of claims 1 to 14~~, characterized in that the rare-earth metal cryptate is a europium cryptate.

17. (Amended) The process as claimed in ~~any one of claims 1 to 16~~, characterized in that the fluorescent conjugate is used as the only label or as one of the fluorescent labels in the assay.

18. (Amended) The process as claimed in ~~any one of claims 1 to 17~~, characterized in that the fluorescent conjugate is bonded covalently to one of the members of a pair of molecules capable of binding specifically to one another, in particular a cellular receptor, an antigen, an antibody or a nucleic acid.

19. (Amended) The process as claimed in ~~any one of claims 1 to 18~~, characterized in that, in addition to said fluorescent conjugate, a fluorescent label comprising an acceptor fluorescent compound in the assay.

1/pstb

Process for reducing the fluorescence quenching caused by the measuring medium

The invention relates to the use of a fluorescent conjugate comprising an oligonucleotide bonded to a rare-earth metal cryptate, for reducing the fluorescence quenching caused by the measuring medium, in a fluorescence assay for an analyte using at least one fluorescent label.

The advancement of knowledge in biology is creating an increasing need for diagnostic methods enabling biomolecules to be monitored or quantified.

At the same time, there is a disaffection toward the radioactive labels which are generally involved in reference assay methods. In general, efforts are currently directed towards replacing radioactive tracers with other labels and mainly with fluorescent labels. The use of fluorescent labels under ideal conditions makes it possible to obtain high sensitivities which are theoretically equivalent to those obtained with radioactive tracers.

In practice, the performance qualities of fluorescent tracers are limited firstly by the presence of a background noise which is often high and, secondly, by the fact that they are generally very sensitive to changes in their environment. Small changes in the pH, the polarity, the presence of dissolved oxygen or the proximity of heavy atoms (iodine for example) or absorbing groups can modify their quantum yield (in the sense of an enhancement or a quenching) or shift the emission wavelength.

It is known that the interaction with proteins present in the serum often causes a quenching of the fluorescence.

The problems inherent to the methods of analysis by measuring fluorescence are listed in a review article (I. Hemmilä, Clin. Chem. 31/3, 359-370 (1985)).

The problems inherent to the background noise arising from the intrinsic fluorescence of proteins and also of other biomolecules present in biological samples may be solved by using fluorescent labels formed from complexes of rare-earth metals (mainly europium) which allow a temporal selection of the specific signal. The particularly long lifetimes (0.1 ms to 1 ms approximately) which characterize europium complexes make it possible, by means of a resolved-time measurement, to be free of the background noise arising, for example, from the serum proteins, this noise being characterized by a relatively short lifetime (about 4 ns).

Indirect labeling of nucleic acids with a trisbipyridine europium [TBP-(Eu<sup>3+</sup>)] cryptate (cryptate described in patent EP 0321353) has been carried out using an anti-DNP antibody labeled with this cryptate, the dinitrophenyl (DNP) group being introduced at the 5' end of synthetic oligonucleotides (E. Lopez et al., Clin. Chem. 39/2, 196-201 (1993)).

The use of antibodies labeled using a TBP-(Eu<sup>3+</sup>) cryptate has, moreover, been extended to the field of immunodiagnosics. The use of a cryptate as a marker has made it possible to develop homogeneous-type immunoassays based on a resolved-time measurement of fluorescence associated with a non-radiative energy transfer (G.Mathis et al., Clin. Chem, 39, 1251 (1993)).

A format of homogeneous type has the considerable advantage of allowing real-time monitoring of the kinetics of formation of an immunological complex, but does not, however, make it possible to be free of any unfavorable interactions between the label and the molecules present in a biological medium (quenching of the fluorescence).

A restoration of the photophysical properties, and in particular the lifetime, may be obtained in a serum medium by adding fluoride ions to the medium, as described in application WO 92/01224.

It has now been found that conjugating a rare-earth metal cryptate molecule to an oligonucleotide chain makes it possible to obtain a cryptate-oligonucleotide fluorescent conjugate which has novel and unexpected photophysical properties.

Said conjugate has the advantageous property of being less sensitive, compared to cryptate alone, to the phenomenon of fluorescence quenching resulting from an interaction with molecules present in the medium.

This observation is of great interest since it enables fluorescence measurements to be performed in biological media without using an adjuvant such as fluoride ions.

The cryptate-oligonucleotide conjugates therefore constitute novel labels, which may be coupled to a biological molecule having a recognition role and which can bind to a partner.

The cryptate-oligonucleotide conjugate coupled to a receptor, such as an antibody or streptavidin, keeps its photophysical properties (resistance to

quenching) and has advantageous properties compared to cryptate-antibody or cryptate-streptavidin conjugates.

According to a first aspect, the invention therefore relates to a process for reducing the fluorescence quenching caused by the measuring medium, in a fluorescence assay for an analyte using at least one fluorescent label, characterized in that a fluorescent conjugate comprising an oligonucleotide bonded to a rare-earth metal cryptate is introduced into the measuring medium.

In an advantageous aspect, the fluorescent conjugate is, itself, used as the only label or as one of the fluorescent labels in the assay.

In the present description, the term "analyte" is intended to mean any substance or group of substances, and also the analogs thereof, which it is desired to detect and/or to determine.

The process as claimed in the invention finds an important application in processes for homogeneous phase assaying "by competition" or "by excess".

In the remainder of the description, the notion of "cryptate" and also the nomenclature for the macrocycles and polycycles which may be used are as defined by J.M. Lehn in Struct. Bonding (Berlin), 16, 1, 1973 and in Acc. Chem. Res. 11, 49, (1978).

In the present description, the term "oligonucleotide" is intended to mean:

- either a chain of ribonucleotide or deoxyribonucleotide units bonded to one another via phosphodiester-type bonds;
- or a chain of ribonucleotide or deoxyribonucleotide units or of analogous units of nucleotides modified on the sugar or on the base and bonded to one another via natural phosphodiester-type internucleotide bonds, some of the internucleotide bonds optionally being replaced with phosphonate, phosphoramidate or phosphorothioate bonds. These various oligonucleotide families are described in Goodchild, *Bioconjugate Chemistry*, 1(3), May/June 1990, 77-99;
- or a chain comprising both ribonucleotides or deoxyribonucleotide units bonded to one another via phosphodiester-type bonds and analogous units of nucleosides bonded to one another via amide bonds, commonly termed "PNAs" (peptide nucleic acids), as described in M. Egholm et al., J. Am. Chem. Soc., 1992, 114, 1895-1897; such compounds are, for example, described in R. Vinayak et al., *Nucleoside & Nucleotide*, 1997, 16 (7-9), 1653-1656.

The use of each of these types of oligonucleotide constitutes an advantageous aspect of the invention.

The term nucleotide "analog" or nucleoside "analog" is intended to mean a nucleotide/nucleoside comprising at least one modification relating to the sugar or the nucleobase, or a combination of these modifications. By way of example, mention may be made of the following modifications:

5

I. Modifications relating to the sugar (nucleotide or nucleoside analogs):

1°) The sugar component may be modified in that the configuration of the hydroxyls (free or involved in a phosphate bridge) is different from the natural configuration (which is, respectively,  $\beta$ -D-*erythro* in a DNA series and  $\beta$ -D-*ribo* in an RNA series), such as, for example, in the analogs with the backbone  $\beta$ -D-*arabino*-pentofuranoside or  $\beta$ -D-*xylo*-pentofuranoside.

2°) The structure may be modified in that the internucleotide bonds are of the 2'  $\rightarrow$  5' type, such as in the case of the  $\beta$ -D-*ribo*-pentofuranoside-2'-phosphate or 3'-deoxy- $\beta$ -D-*erythro*-pentofuranoside-2'-phosphate derivatives.

Nucleotides exist in which the structure includes the two modifications above, such as  $\beta$ -D-*xylo*-pentofuranoside-2'-phosphate.

3°) The structure may differ from the natural model in that the 4' carbon has an opposite configuration, which is the case for  $\alpha$ -L-*threo*-pentofuranoside-3'-phosphate. The difference may relate to the configuration of the carbon in 1' (anomeric position), which is the case for  $\alpha$ -D-*erythro*-pentofuranoside-3'-phosphate. Nucleotides/nucleosides exist in which the structure includes the two modifications above, such as  $\beta$ -L-*threo*-pentofuranoside-3'-phosphate.

4°) The structure may differ from the natural model in that the oxygen in 4' is replaced with a carbon (carbocyclic analog) or with a sulfur, such as 4'-thio- $\beta$ -D-*erythro*-pentofuranoside-3'-phosphate.

5°) The structure may differ from the natural model in that one of the hydroxyls of the sugar is alkylated, for example in the backbone 2'-O-alkyl- $\beta$ -D-*ribo*-pentofuranoside-3'-phosphate, the alkyl group possibly being a methyl or allyl group, for example.

6°) The structure may differ from the natural model in that only the sugar component is conserved, such as in 1,2-dideoxy-D-*erythro*-pentofuranose-3'-phosphate, or in that the sugar is replaced with a polyol such as propanediol.



II. Modifications relating to nucleobase (nucleotide analogs):

1°) The nucleobase may be modified in that the substituents of the natural bases are modified, such as in 2,6-diaminopurine, hypoxanthine, 4-thiothymine, 4-thiouracil or 5-ethynyluracil.

2°) The positions of the substituents may be switched in comparison with the natural bases, such as in isoguanosine or isocytosine.

3°) A nitrogen atom of the nucleobase may be replaced with a carbon atom, such as in 7-deazaguanosine or 7-deazaadenine.

Furthermore, as mentioned above, the bonds between the sugar units or the analogs thereof may also be modified, for example by replacing one or more of the oxygen atoms of the natural phosphodiester bond with a carbon (phosphonate series), a nitrogen (phosphoramidate series) or a sulfur (phosphorothioates).


Advantageously, the oligonucleotide of the conjugate as claimed in the invention consists of ribonucleotide or deoxyribonucleotide units, one of which may comprise a functional group introduced or generated on said unit, or a functional group introduced using a spacer arm bonded to the terminal phosphate group in the 3' or 5' position.

According to a preferred aspect, said unit is the 5' terminal unit or 3' terminal unit.

The oligonucleotide which may be used according to the invention will preferably comprise a chain of 5 to 50 nucleotides or a chain of 5 to 50 nucleotides and nucleotide or nucleoside analogs as defined above.

According to a particular aspect of the invention, use will be made of an oligonucleotide consisting of a chain of ribonucleotide or deoxyribonucleotide units bonded to one another via phosphodiester-type bonds, and of analogous units of nucleosides bonded to one another via amide bonds, said oligonucleotide comprising at least 5 phosphodiester-type internucleotide bonds at the end intended to be bonded to the cryptate.

According to a preferred aspect, said rare-earth metal cryptate consists of at least one rare-earth metal salt complexed with a macropolycyclic compound of formula







- in which Z is an atom with 3 or 4 valencies, R is nothing or represents hydrogen, a hydroxy group, an amino group or a hydrocarbon-based radical, the divalent radicals (A), (B) and (C), are, independently of each other, hydrocarbon-based chains which optionally contain one or more hetero atoms and are optionally interrupted with a hetero macrocycle, at least one of the radicals (A), (B) and (C), also comprising at least one molecular unit or consisting essentially of a molecular unit, said molecular unit having a triplet energy which is greater than that of the emission level of the complexed rare-earth metal ion.

In particular, said rare-earth metal cryptate corresponds to formula (I) in which the molecular unit is chosen from phenanthroline, anthracene, benzene, naphthalene, biphenyl and terphenyl, azobenzene, azopyridine, pyridine, bipyridines, bisquinolines and the compounds of the formula below:

- C<sub>2</sub>H<sub>4</sub> - X<sub>1</sub> - C<sub>6</sub>H<sub>4</sub> - X<sub>2</sub> - C<sub>2</sub>H<sub>4</sub> -  
 - C<sub>2</sub>H<sub>4</sub> - X<sub>1</sub> - CH<sub>2</sub> - C<sub>6</sub>H<sub>4</sub> - CH<sub>2</sub> - X<sub>2</sub> - C<sub>2</sub>H<sub>4</sub> -

X<sub>1</sub> and X<sub>2</sub>, which may be identical or different, denote oxygen, nitrogen or sulfur,



X being oxygen or hydrogen.

- Advantageously, said rare-earth metal cryptate consists of a rare-earth metal salt complexed with one of the macrocyclic compounds below:

- (22)phenanthroline; (22)phenanthrolineamide; (22)anthracene;  
 (22)anthracenamide; (22)biisoquinoline; (22)biphenylbispyridine; (22)bipyridine;  
 (22)bipyridinamide; the macropolycycles trisbipyridine, trisphenanthroline,  
 phenanthrolinebisbipyridine, biisoquinolinebisbipyridine, bisbipyridine  
 10 diphenylbipyridine.

Such compounds are, for example, described in patent EP 180 492.



- Use may also be made of the macropolycyclic cryptate compounds which complex rare-earth metal ions, in which the molecular unit is chosen from bipyrazines, bipyrimidines and nitrogen-containing heterocycles comprising N-oxide groups.

Macropolycyclic compounds containing bipyrazine units are described in F. Bodar-Houillon et al., New J. Chem., 1996, 20, 1041-1045.

Macropolycyclic compounds containing bipyrimidines are described in J. M. Lehn et al., Helv. Chim. Acta, 1992, 75, 1221.


Macropolycyclic compounds comprising nitrogen-containing heterocycles comprising N-oxide groups are described in J.M. Lehn et al., *Helv. Chim. Acta*, 1991, 74, 572.

- 5 In another advantageous aspect, said rare-earth metal cryptate consists of at least one rare-earth metal salt complexed with a macropolycyclic compound corresponding to one of the formulae II or III below:





in which:

- the ring of formula



is one of the following rings:



5

- Y is a spacer group or spacer arm which consists of a divalent organic radical, chosen from linear or branched  $C_1$  to  $C_{20}$  alkylene groups optionally containing one or more double bonds and/or optionally containing one or more hetero atoms such as oxygen, nitrogen, sulfur or phosphorus or one or more carbamoyl or carboxamido group(s); chosen from  $C_5$  to  $C_8$  cycloalkylene groups or chosen from  $C_6$  to  $C_{14}$  arylene groups, said alkylene, cycloalkylene or arylene groups being optionally substituted with alkyl, aryl or sulfonate groups;

- Z is a functional group capable of bonding covalently to a biological substance;

- R is a methyl group or represents the group -Y-Z;

- R' is hydrogen or a group -COOR'' in which R'' is a  $C_1$  to  $C_{10}$  alkyl group and preferably represents a methyl, ethyl or tert-butyl group, or alternatively R' is a group -CO-NH-Y-Z.

According to a preferred aspect, the rare-earth metal cryptate of the fluorescent conjugate used according to the invention is a europium cryptate.

In an advantageous aspect, said rare-earth metal cryptate is the europium cryptate Eu trisbipyridine or Eu [bisdiethoxybipyridine.bipyridine].

The rare-earth metal cryptate is preferably bonded covalently to the oligonucleotide either directly or via a spacer arm.


The term "direct bonding" is intended to mean the bonding of the fluorescent label to a functional group which has been introduced onto or generated, beforehand, on one or more atoms of a base or of a pentofuranose unit of the oligonucleotide.

In the present description, the term "functional group" denotes any function which is borne by the nucleotide component or introduced onto this component by any means known to those skilled in the art, and which is capable of bonding, by covalent bonding, directly or after activation, to a function present on the cryptate or on the spacer arm borne by the cryptate. Such functional groups are in particular the  $\text{NH}_2$ ,  $\text{COOH}$ ,  $\text{CHO}$ ,  $\text{OH}$  or  $\text{SH}$  functions and also the functions capable of providing covalent bonds by substitution (halides, sulfonates, epoxide) or by addition (double bonds of the maleimide type). These functions are generally borne by a hydrocarbon-based chain which is, itself, bonded to the nucleotide component.

Methods for introducing these functional groups are in particular described in C. Kessler, *Nonisotopic probing, Blotting and Sequencing*, 2<sup>nd</sup> edition, L.J. Kricka (1995), Ed. Academic Press Ltd., London, p. 66-72. According to a preferred aspect of the invention, the rare-earth metal cryptate is bonded to the oligonucleotide via a spacer arm. The term "spacer arm" is intended to mean any means for covalently attaching the oligonucleotide to the cryptate via a terminal phosphate, via an atom of a purine or pyrimidine base or via an atom of the sugar.

In an advantageous aspect, said spacer arm consists of a divalent organic radical chosen from  $\text{C}_1$ - $\text{C}_{20}$  linear or branched alkylene groups optionally containing one or more double bonds or triple bonds and/or optionally containing one or more hetero atoms, such as oxygen, nitrogen, sulfur, phosphorus or one or more carbamoyl or carboxamido group(s);  $\text{C}_5$ - $\text{C}_8$  cycloalkylene groups and  $\text{C}_6$ - $\text{C}_{14}$  arylene groups, said alkylene, cycloalkylene or arylene groups being optionally substituted with alkyl, aryl or sulfonate groups.

In particular, the spacer arm is chosen from the groups of formulae:



in which  $n = 2$  to  $6$ , and  $-\text{CONH}-(\text{CH}_2)_6-$ ,

the attachment via the group  $-\text{CONH}$  taking place on the cryptate.

- According to a further aspect of the invention, the fluorescent conjugate is bonded covalently to one of the members of a pair of molecules capable of binding specifically to one another, such as for example and antigen/antibody pair, a ligand/cellular receptor pair, a biotin/avidin pair, or a pair consisting of a nucleic acid (in particular a single-stranded or double-stranded RNA or DNA, or a single-stranded or double-stranded oligonucleotide) and the nucleic acid comprising the bases complementary thereto.

According to one aspect of the process as claimed in the invention, the fluorescence of the fluorescent conjugate used as a label is emitted directly by the fluorescent label, after excitation at a given wavelength.

- According to another aspect of the process as claimed in the invention, another fluorescent label, besides said fluorescent conjugate, is used in the assay. In this case, the fluorescence measured in the assay is emitted indirectly by a nonradiative energy transfer between the conjugate after excitation, termed "donor compound", and another fluorescent molecule, termed "acceptor compound".

In this particular case, the following conditions are satisfied:

- firstly, the acceptor fluorescent compound has an absorption spectrum which covers at least partially the emission spectrum of the donor and has a high molar absorbance in this covering range, and an emission spectrum which is in a wavelength range in which the donor exhibits low intrinsic emission;
- secondly, the acceptor and the donor are close to one another, the orientation of their transition dipoles being approximately parallel.

The principle of the technique of non-radiative energy transfer is described in particular in G. Mathis et al., Clin. Chem., 1993, 39, 1953-1959.

The rare-earth metal cryptate bonded to the oligonucleotide in the conjugate, which is the donor fluorescent compound, may, in this case, be a  
 5 europium cryptate, and the acceptor fluorescent compound may, for example, be chosen from allophycocyanin, allophycocyanin B, C-phycocyanin or R-phycocyanin.

The invention is illustrated using the examples below, in which the following abbreviations will be used:

- 10 BSA : bovine serum albumin  
 DTT : dithiothreitol  
 SMCC : N-hydroxysuccinimide ester of 4-(N-maleimidomethyl)cyclohexane-1-carboxylic acid  
 SMP : N-hydroxysuccinimide ester of 3-maleimidopropionic acid  
 15 SPDP : N-succinimidyl-3-(2-pyridyldithio)propionate  
 NBFCS : newborn fetal calf serum  
 TEAB : triethylammonium bicarbonate  
 TEA Ac : triethylammonium acetate containing 10% acetonitrile  
 TCEP : tris(2-carboxyethyl)phosphine.

20

**EXAMPLE 1. Photophysical properties of a free cryptate [TBP-(Eu3+)] in the presence of serum:**

Method A: The fluorescence spectra and the lifetimes are measured on a  
 25 Perkin-Elmer spectrofluorimeter of the LS50 type.

A stock solution ( $9 \times 10^{-6}$  M concentration in 100 nM phosphate buffer, pH 7) of cryptate [TBP-(Eu3+)]-diamine (purified by RP-HPLC on a C-18 column with a linear gradient of acetonitrile in water containing 1% trifluoroacetic acid and then dried under vacuum), prepared by reacting ethylenediamine on the cryptate  
 30 [(bisbpy)-(bpy-dimethylester)] described in example 4, section A of application EP 0 321 353, is prepared. In the following examples, this cryptate [TBP-(Eu3+)]-diamine will be abbreviated to K-NH<sub>2</sub>.



- 1°) 200 µl of this stock solution is diluted in 400 µl of 100 mM phosphate buffer, pH 7 and the fluorescence spectrum ( $t_d = 0.1$  ms,  $t_g = 0.4$  ms,  $\lambda_{excitation} = 306$  nm,  $\lambda_{emission} = 540$  to 750 nm, excitation/emission slits = 10/5, yellow filter at emission) and the lifetime  $t$  ( $t_d = 0.1$  to 0.6 ms,  $t_g = 0.4$  ms,  $\lambda_{excitation} = 306$  nm,  $\lambda_{emission} = 620$  nm, excitation/emission slits = 10/5, yellow filter at emission) are measured:

It is observed that the main line ( $\lambda_{em} = 616$  nm) has a lifetime in the phosphate buffer of  $t_p = 0.60$  ms (Correlation Coefficient C.C = 0.999).

- 2°) 200 µl of this stock solution of K-NH<sub>2</sub> are diluted in a mixture of 200 µl of 100 mM phosphate buffer, pH 7 and 200 µl of NBFCs, and the spectrum and lifetime are measured under the same conditions.

It is observed that the main line ( $\lambda_{em} = 616$  nm) has a lifetime in the phosphate buffer of  $t_s = 0.15$  ms (C.C = 0.991).

- The quenching factor is given by the expression  $Q = 100 - 100(t_s/t_p)$ , namely  $Q = 100 - 100(0.15/0.60) = 75$ , namely 75% quenching.

#### Method B :

- A stock solution of cryptate [TBP-(Eu3+)]-diamine in 100 mM phosphate buffer at a concentration of  $1.8 \times 10^{-8}$  M is prepared.

The wells of a black-bottomed microplate (96-well HTRF plate, Packard) are filled according to the following protocol:

- Condition 1 : 100 µl of stock solution of cryptate are mixed with 100 µl of 100 mM phosphate buffer, pH 7 and 100 µl of 100 mM phosphate buffer, pH 7, containing 0.15 M NaCl and 0.1% BSA; the measurements are performed in duplicate. This medium constitutes a reference.

- Condition 2 : 100 µl of stock solution of cryptate are mixed with 100 µl of NBFCs and 200 µl of 100 mM phosphate buffer, pH 7, containing 0.15 M NaCl and 0.1% BSA (measurement in duplicate).

- Resolved-time measurement of the fluorescence is performed on a DISCOVERY machine (Packard) using a laser excitation at 337 nm and an acquisition window of 50 µs to 400 µs.

In the phosphate buffer alone (condition 1), it is observed that the intensity of the emission at 620 nm is  $1.41 \times 10^5$  afu (arbitrary fluorescence units). In the

adjacent wells of the same microplate, the solutions containing serum (condition 2) exhibit an intensity of the emission at 620 nm of  $2.9 \times 10^4$  afu.

- The decrease in the intensity of the signal at 620 nm in the presence of serum compared to the reference in the phosphate buffer makes it possible to demonstrate the phenomenon of quenching caused by the serum.

$$100-100[E_{620}(\text{serum})/E_{620}(\text{ref})] = 100-100(2.9 \times 10^4/1.41 \times 10^5) = 80\%$$

This method allows an overall estimation of the decrease in the signal which comes either from a decrease in the lifetime or from a decrease in the emission at 620 nm.

- It makes it possible to work at lower concentrations compared to method A and allows simultaneous measurement of several samples by carrying out the procedure under conditions which are as close as possible to those encountered in an immunoassay.

## 15 **EXAMPLE 2. Synthesis and purification of an oligodeoxynucleotide-cryptate [TBP-(Eu3+)]:**

1°) Synthesis of an oligodeoxynucleotide functionalized with an aminoethyl arm (AH-ODN1):

- An oligodeoxynucleotide (ODN) of sequence  $5'\text{-}^{14}\text{C}$  ACG CCA CTA GCT CC-<sub>3</sub> modified in its 5' end with an aminoethyl (AH) arm is synthesized on a solid support via the phosphite-phosphoramidite method using a DNA synthesizer (Applied Biosystems type 392) according to the manufacturer's protocol. A modified nucleotide is introduced in 5' by coupling an N,N-diisopropyl-β-cyanoethyl-phosphoramidite obtained from 5'-O-(4,4'-dimethoxytrityl)-N-4-(6-trifluoroacetamidoheptyl)-2'-deoxycytidine prepared by trifluoroacetylation of 5'-O-(4,4'-dimethoxytrityl)-N-4-(6-aminoheptyl)-2'-deoxycytidine as described in Roget et al. Nucleic Acids Res., 17, 7643-7650, (1989).

- After synthesis on a DNA synthesizer (Applied Biosystem 392) in the "trityl-on" mode following the corresponding user guide, the oligonucleotide is treated with concentrated aqueous ammonia (16 h at 55°C) and purified by HPLC on an LiChrospher® RP-18E 250-10 column (10 μm) (Merck, Darmstadt, Germany) with a gradient of acetonitrile in 50 mM triethylammonium acetate (buffer A: 5% acetonitrile, buffer B: 50% acetonitrile; flow rate 5 ml/min, gradient of 10% B to 60%

B in 20 min, 60% B isocratic gradient for 5 min, and then gradient of 60% B to 100% B in 5 min), according to the method described in Oligonucleotide synthesis: A practical approach. Ed M.J. Gait. IRL Press, Oxford. The fractions corresponding to a major peak (retention time greater than 20 min) are evaporated. After evaporation and co-evaporation with water, the partially deprotected oligonucleotide thus obtained is detritylated with 80% acetic acid (room temperature, 30 min), then, after evaporation and coevaporation, the completely deprotected oligonucleotide is taken up in 50  $\mu$ l of 100 mM triethylammonium bicarbonate (TEAB), pH 8, and precipitated with 1.5 ml of n-butanol. After centrifugation, the supernatant is discarded and the precipitate dried under vacuum is taken up with 200  $\mu$ l of water. This stock solution (oligonucleotide termed AH-ODN1) has an absorption of 37 AU<sub>260</sub>/ml.

2°) Coupling of a molecule of cryptate [TBP-(Eu3+)] to an oligodeoxynucleotide functionalized with an aminohexyl arm (AH-ODN1):

An aliquot portion (150  $\mu$ l) of the stock solution of the oligonucleotide obtained above (5.5 AU<sub>260</sub>, i.e. about 39 nmol) is diluted with 150  $\mu$ l of a 0.1 M aqueous TEAB solution, pH 7.8, and 60  $\mu$ l of a solution of activated cryptate [TBP-(Eu3+)] (4 mg/ml), i.e. 171 nmol (about 4 equivalents) are added. The activated (N-hydroxysuccinimide/dicyclohexylcarbodiimide) cryptate [TBP-(Eu3+)] is prepared extemporaneously from [(bisbipy)-(bipy diacid)] europium cryptate, itself obtained from the [(bisbipy)-(bipy dimethyl ester)] europium cryptate described in example 4, section A of application EP 0 321 353.

After 30 min with stirring, 15  $\mu$ l of 1M TEAB, pH 8.5, are added, followed by evaporation under vacuum (speed-vac) until a volume of 200  $\mu$ l is obtained, this is loaded onto an NAP10 column (Pharmacia) equilibrated in 25 mM TEAAc buffer, pH 7, containing 10% acetonitrile, elution is then carried out with the same buffer according to the manufacturer's protocol, the fraction excluded is collected in a volume of 1 ml and this fraction is concentrated (speed-vac) until a volume of 200  $\mu$ l is obtained.

3°) Purification of a conjugate formed from a cryptate [TBP-(Eu3+)] and from an oligodeoxynucleotide functionalized with an aminohexyl arm (conjugate KH-ODN1):

The conjugate KH-ODN1 is analyzed by FPLC on a mono-Q column (Pharmacia) using the following conditions (buffer C: 20 mM sodium acetate, pH 5,

containing 10% acetonitrile. Buffer D: 20 mM sodium acetate, pH 5, 1 M lithium chloride containing 10% acetonitrile. Gradient: 0 to 2 min isocratic 20% D, 2 min to 30 min gradient of 20% D to 60% D, flow rate 1 ml/min).

The oligonucleotide AH-ODN1 analyzed by FPLC under the conditions  
 5 above exhibits a retention time  $R_t = 16.4$  min. Under the same conditions, the conjugate KH-ODN1 exhibits a retention time  $R_t = 15.4$  min.

The entire excluded fraction from the NAP10 column (200  $\mu$ l) is then injected onto the mono-Q column, and the fraction corresponding to a retention time of 15 min is collected, concentrated down to 300  $\mu$ l and desalified on a NAP10  
 10 column equilibrated in a 25 mM TEAAc buffer, pH 7, containing 10% acetonitrile. Elution is carried out using the same buffer according to the manufacturer's protocol and the excluded fraction is collected in a volume of 1 ml. This fraction corresponds to the pure conjugate KH-ODN1 and is characterized by an ultraviolet spectrum which exhibits a maximum at 258 nm (ODN component) and a shoulder around  
 15 305 nm (cryptate component); the absorbance ratio  $A_{260}/A_{305} = 4.46$  is close to the theoretical ratio obtained by calculating the ratio of the molar absorbances of the components of the conjugate taken individually  $\epsilon_{260}(\text{ODN}) + \epsilon_{260}(\text{cryptate}) / \epsilon_{305}(\text{cryptate}) = (135\,000 + 19\,000) / 30\,000 \simeq 5$ .

The structure of the conjugate KH-ODN1 is represented in figure 1.  
 20

4°) Synthesis of a cryptate-oligonucleotide conjugate (K-ODN2) :

The synthesis is repeated according to the protocol above, constructing the oligonucleotide sequence GGG GGT TTT TTT TTT ( $G_5T_{10}$ ) in place of ACG CCA CTA GCT CC.  
 25

### **EXAMPLE 3. Photophysical properties of an oligonucleotide-cryptate [TBP-(Eu3+)] conjugate in the presence of serum:**

Method A : The fluorescence spectra and the lifetimes are measured on a  
 30 Perkin-Elmer spectrofluorimeter of the LS50 type.

The stock solution of oligonucleotide-cryptate [TBP-(Eu3+)] conjugate obtained in example 2 (3°) is used, while considering the concentration estimated by measuring absorbance  $\epsilon_{260}(\text{conjugate}) = \epsilon_{260}(\text{ODN}) + \epsilon_{260}(\text{cryptate}) \simeq (154\,000)$  to be  $3.5 \times 10^{-6}$  M.

1°) 200  $\mu$ l of this stock solution is diluted either in water or in 400  $\mu$ l of 100 mM phosphate buffer, pH 7, and the fluorescence spectrum ( $t_d = 0.1$  ms,  $t_g = 0.4$  ms,  $\lambda_{excitation} = 306$  nm  $\lambda_{emission} = 540$  to 750 nm, excitation/emission slits = 10/5, yellow filter at emission) and also the lifetime  $\tau$  ( $t_d = 0.1$  to 0.6 ms,  $t_g = 0.4$  ms,  $\lambda_{excitation} = 306$  nm,  $\lambda_{emission} = 620$  nm, excitation/emission slits = 10/5, yellow filter at emission) are measured:

In water or in the phosphate buffer, a spectrum profile is observed which is different from that conventionally observed for the cryptate [TBP-(Eu3+)]-diamine: the main line ( $\lambda_{em} = 620$  nm) has a lifetime of  $t_p = 1.1$  ms (Correlation Coefficient C.C = 0.999).

2°) 200  $\mu$ l of this stock solution are diluted in a mixture of 200  $\mu$ l of 100 mM phosphate buffer, pH 7, and of 200  $\mu$ l of NBFCs and the spectrum and lifetime are measured under the same conditions.

It is observed that the main line ( $\lambda_{em} = 620$  nm) has a lifetime in the phosphate buffer of  $t_p = 1.1$  ms (C.C = 0.99).

In this case, no extinction by reduction of the lifetime is observed.

## Method B :

The stock solution of oligonucleotide-cryptate [TBP-(Eu3+)] conjugate as obtained in example 2 (3°) is used. By measuring absorbance at 260 nm, the concentration is estimated to be  $3.5 \times 10^{-6}$  M. This stock solution is diluted in 100 mM phosphate buffer in order to obtain a final concentration of  $2 \times 10^{-8}$  M.

The wells of a black-bottomed microplate (HTRF 96-well plate, Packard) are filled according to the following protocol:

Condition 1 : 100  $\mu$ l of stock solution of conjugate K-ODN1 are mixed with 100  $\mu$ l of 100 mM phosphate buffer, pH 7, and 200  $\mu$ l of 100 mM phosphate buffer, pH 7, containing 0.15 M NaCl and 0.1% BSA; the measurements are carried out in duplicate. This medium constitutes a reference.

Condition 2 : 100  $\mu$ l of stock solution of conjugate K-ODN1 are mixed with 100  $\mu$ l of NBFCs and 100  $\mu$ l of 100 mM phosphate buffer, pH 7, containing 0.15 M NaCl and 0.1% BSA (measurement in duplicate).

Resolved-time measurement of the fluorescence is performed on a DISCOVERY machine (Packard) using a laser excitation at 337 nm and an acquisition window of 50  $\mu$ s to 400  $\mu$ s.

In the phosphate buffer alone (condition 1), it is observed that the intensity of the emission at 620 nm is  $2.8 \times 10^5$  afu (arbitrary fluorescence units). In the adjacent wells of the same microplate, the solutions containing serum (condition 2) exhibit an intensity of the emission at 620 nm of  $2.8 \times 10^5$  afu.

In this case, no decrease in the intensity of the signal at 620 nm is observed in the presence of serum compared to the reference in the phosphate buffer. There is, therefore, no phenomenon of quenching caused by the serum.

The quenching calculated using the following formula is:

$$100 - 100[E_{620}(\text{serum}) / E_{620}(\text{ref})] = 100 - 100(2.8 \times 10^5 / 2.8 \times 10^5) = 0\%$$

**EXAMPLE 4. Compared photophysical properties of an oligonucleotide-cryptate conjugate and of a reference cryptate [TBP-(Eu3+)], in the presence of uric acid:**

This example is used to compare the effect of uric acid on the photophysical properties of various molecules containing a europium cryptate unit.

Identical volumes (100  $\mu$ l) either of a solution of cryptate-labeled conjugate (about  $2 \times 10^{-8}$  M, see example 3B), the evaluation of which is desired, or of a reference cryptate solution (about  $2 \times 10^{-8}$  M, see example 1B) are pipetted into a series of wells of a microplate.

In each series of wells, 200  $\mu$ l of 100 mM phosphate buffer, pH 7, containing 0.15 M NaCl and 0.1% BSA are added to the first well (standard 0) and 200  $\mu$ l of solutions containing increasing concentrations of uric acid in the same buffer are added to the subsequent wells (in order to obtain, for example, final concentrations of 0, 5, 10, 20, 40 and 80 mg/l of uric acid).

The fluorescence is measured in resolved time on a DISCOVERY machine (Packard) using a laser excitation at 337 nm and an acquisition window of 50  $\mu$ s to 400  $\mu$ s.

For each series, the intensity of the emission at 620 nm is measured for the standard 0 and also for each concentration of uric acid. For each concentration, the percentage quenching is evaluated using the following relationship:

100-100[E<sub>620</sub> (uric acid) / E<sub>620</sub>(standard 0)]

The results are given in table 1.

TABLE 1

5

[Uric acid] in mg/l	% quenching at 620 nm	
	K-NH2	K-G5T10
0	0	0
1.25	47	8
2.5	66	20
5	79	28
10	86	30
20	88	36
40	89	40
80	90	46


- It is observed that the percentage quenching of the reference free cryptate greatly increases as a function of the concentration of uric acid. On the other hand, the percentage quenching of the cryptate-oligonucleotide conjugates is significantly lower even for the highest concentrations of uric acid.


Specifically, at the concentration of 5 mg/ml, the reference cryptate K-NH2 exhibits 79% quenching whereas, under the same conditions, the cryptate-oligonucleotide conjugate K-ODN2 exhibits only 28% quenching.

15 **EXAMPLE 5. Synthesis and purification of a cryptate [TBP-(Eu3+)]-aminohexyl-oligonucleotide-maleimide conjugate:**

- Synthesis of an oligonucleotide of sequence G<sub>5</sub>T<sub>10</sub> functionalized in its 5' end with a cryptate and in its 3' end with an arm bearing a maleimide reactive group (5'-**K-AH** GGG GGT TTT TTT TT<sup>MCCAH</sup> C T-3').

The synthesis is carried out using an oligonucleotide bearing two aminohexyl arms, one of which is protected (general structure MMT-NH-(CH<sub>2</sub>)<sub>6</sub>-(<sup>5</sup>ODN<sub>3</sub>)-(CH<sub>2</sub>)<sub>6</sub>-NH<sub>2</sub>), according to the scheme below.





An oligodeoxynucleotide (ODN) of sequence  ${}^5\text{MMT-AH GGG GGT TTT TTT TT}^{\text{AH}}\text{C T-3}$ , modified in its 5' end with an aminohexyl (AH) arm in the form in which it is protected with a monomethoxytrityl (MMT) group, is synthesized according to the following process:

The N,N-diisopropyl- $\beta$ -cyanoethylphosphoramidite derivative of 5'-O-(4,4'-dimethoxytrityl)-N-4-(6-trifluoroacetamidoethyl)-2'-deoxycytidine is coupled to a T column (1  $\mu\text{mol}$ ) using a process similar to example 1 (1°), then the synthesis is continued by constructing the sequence GGG GGT TTT TTT TT and, finally, a monomethoxytritylaminoethylphosphoramidite derivative (MMT-C6—amino modifier, Cruachem) is coupled using the "trityl-ON" option of the synthesizer. The oligonucleotide  ${}^5\text{MMT-AH GGG GGT TTT TTT TT}^{\text{AH}}\text{CT}$  is treated with concentrated aqueous ammonia (16 h at 55°C) and purified by HPLC according to the protocol of example 1 (1°).

The partially deprotected oligonucleotide thus obtained is concentrated (speed-vac) and an aliquot portion (0.24  $\mu\text{mol}$ ) is taken up with 100  $\mu\text{l}$  of 0.1 M phosphate buffer, pH 8, and treated with 5 mg of SMCC (15  $\mu\text{mol}$ ) in 100  $\mu\text{l}$  of acetonitrile (Sigma). After 40 min with stirring at room temperature, the mixture is concentrated to half its volume (speed-vac) and desalified on an NAP10 column equilibrated in 25 mM TEAAc, pH 7, 5% acetonitrile. The excluded fraction (1 ml) containing the oligonucleotide of structure  ${}^5\text{MMT-AH GGG GGT TTT TTT TT}^{\text{MCC-AH}}\text{CT}$  is evaporated to dryness, the residue is taken up with 1 ml of 80% acetic acid and after 20 min at room temperature, the mixture is concentrated and coevaporated (speed-vac) with water and then taken up in 300  $\mu\text{l}$  of water. At this stage, the detritylated oligonucleotide with the following structure  ${}^5\text{AH GGG GGT TTT TTT TT}^{\text{MCC-AH}}\text{CT}$  is obtained.

This oligonucleotide (0.175  $\mu\text{mol}$  in 300  $\mu\text{l}$ ) is diluted with 300  $\mu\text{l}$  of 0.1 M TEAB, pH 7, and then 450  $\mu\text{l}$  (1.27 nmol, i.e.  $\sim 7$  eq.) of a solution of activated cryptate [TBP-(Eu3+)] (4 mg/ml) as described in example 2 are added.

After 30 min of stirring, the mixture is evaporated under vacuum (speed-vac) until a volume of 200  $\mu\text{l}$  is obtained, this is loaded onto an NAP10 column (Pharmacia) equilibrated in a 25 mM TEAAc buffer, pH 7, containing 10% acetonitrile and elution is carried out with the same buffer according to the manufacturer's protocol. The excluded fraction is collected in a volume of 1 ml and



concentrated (speed-vac) until a volume of 200  $\mu$ l is obtained. The excluded fraction contains mainly the labeled oligonucleotide of structure ( $^5$ -**K-AH** GGG GGT TTT TTT TT  $^{MCC-AH}$ C T $_{-3}$ ); this oligonucleotide is purified by injection onto an HR 10/30 column filled with Sephadex G25 which is eluted with 0.1 M phosphate buffer, pH 7, with a flow rate of 1 ml/min. The fraction eluted between 8 and 11 min is collected. 3 ml are thus obtained of a solution containing 17.5 nmol of the pure oligonucleotide  $^5$ -**K-AH** GGG GGT TTT TTT TT  $^{MCC-AH}$ C T $_{-3}$  which can be directly used for coupling to the thiol functions of a protein ( $A_{260}/A_{305}$  ratio = 7).

**EXAMPLE 6. Coupling of a cryptate [TBP-(Eu3+)]-aminohexyl-oligonucleotide-maleimide conjugate to an antibody:**

An antibody is functionalized with an SPDP (Pierce), after reduction with DTT, the activated antibody is purified on an HR 10/30 column filled with Sephadex G25 which is eluted with 0.1 M phosphate buffer, pH 7 with a flow rate of 1 ml/min. The fraction containing the activated antibody is combined with a cryptate-oligonucleotide conjugate activated with a maleimide group  $^5$ -**K-AH** GGG GGT TTT TTT TT  $^{MCC-AH}$ C T $_{-3}$ , prepared according to example 5. The reaction mixture is then purified on a Superdex 200 column which is eluted as above and the fraction containing the antibody-oligonucleotide-cryptate conjugate is collected.

**EXAMPLE 7. Coupling of a cryptate [TBP-(Eu3+)]-aminohexyl-oligonucleotide-maleimide conjugate to streptavidin:**

The streptavidin is activated as in example 6 and it is then labeled using a cryptate-oligonucleotide conjugate activated with a maleimide group  $^5$ -**K-AH** GGG GGT TTT TTT TT  $^{MCC-AH}$ C T $_{-3}$ , prepared according to example 5.

**EXAMPLE 8. Photophysical properties of a protein-oligonucleotide-cryptate [TBP-(Eu3+)] conjugate:**

The percentage quenching is evaluated in the presence of uric acid according to the protocol of example 4.

A cryptate [TBP-(Eu3+)]-oligonucleotide-antibody conjugate prepared according to the protocol of example 6 is thus evaluated in comparison with a

reference cryptate [TBP-(Eu3+)]-antibody prepared by labeling an antibody using cryptate (activated with SMCC) according to a conventional immunochemistry protocol.

- 5 A cryptate [TBP-(Eu3+)]-oligonucleotide-streptavidin conjugate prepared according to example 7 is also evaluated in comparison with a reference cryptate [TBP-(Eu3+)]-streptavidin prepared by labeling streptavidin using cryptate (activated with SMCC) according to a conventional immunochemistry protocol.

The results are given in table 2.

TABLE 2

[Uric acid] in mg/l	Percentage quenching of the signal from the cryptate trisbipyridine at 620 nm	
	Anti-prolactin cryptate trisbipyridine conjugate	Anti-prolactin oligonucleotide cryptate trisbipyridine conjugate
0	0	0
5	46	2
10	61	9
20	71	15
40	82	20
80	86	28

[Uric acid] in mg/l	Percentage quenching of the signal from the cryptate trisbipyridine at 620 nm	
	Streptavidin cryptate trisbipyridine conjugate	Streptavidin oligonucleotide cryptate trisbipyridine conjugate
0	0	0
5	74	10
10	88	11
20	94	18
40	97	23
80	97	32


It is observed that, for the high concentrations of uric acid, the reference cryptate-antibody conjugate exhibits 86% quenching whereas, under the same conditions, the cryptate-oligonucleotide-antibody conjugate exhibits only 28% quenching. For a neighboring concentration of uric acid of between 5 and 10 mg/ml, the fluorescence of the reference conjugate is attenuated by 50% whereas the compound of the invention exhibits less than 10% quenching.

Similarly, it is observed that, under the conditions of a high concentration of uric acid, the reference cryptate-streptavidin conjugate exhibits 97% quenching whereas the cryptate-oligonucleotide-streptavidin conjugate exhibits only 32% quenching.

**EXAMPLE 9. Coupling of a cryptate [TBP-(Eu3+)]-maleimide conjugate to a thiol-oligonucleotide:**


The cryptate [(bisbipy)-(bipy dimethyl ester)] described in example 4, section A of application EP 0 321 353 is treated with ethylenediamine and the resulting cryptate diamine purified by RP-HPLC is then treated with SMCC (Pierce) or SMP (Pierce) so as to introduce a maleimide group. A cryptate-maleimide conjugate is thus obtained. This cryptate-maleimide conjugate, purified on RP-HPLC, is coupled to a thiol-oligonucleotide (ODN4 below).

The oligonucleotide used has the following structure:



The thiol function is introduced in 5' of the oligonucleotide in the form of a disulfide bridge. This functionalization is introduced at the end in the 5' position of the oligonucleotide via a phosphoramidite (C6-disulfide phosphoramidite, Cruachem Ltd., Glasgow). After ammoniacal deprotection and purification (RP-HPLC), the oligonucleotide is treated with TCEP (Pierce, Rockford, IL) in order to free the thiol function.

The oligonucleotide with the following structure is thus obtained:



15  $\mu\text{l}$  of a solution of ODN3 at 156 AU<sub>280</sub>/ml are added to 85  $\mu\text{l}$  of water, 50  $\mu\text{l}$  of a 1 mg/ml solution of TCEP are added, after 20 min at 20°C the mixture is loaded onto an NAP 10 column (equilibrated in 25 mM TEAAc, pH 7, 5% acetonitrile), the column is eluted, the exclusion volume (1 ml containing about

9 nmol of ODN4) is collected and concentrated in a speed-vac (down to about 100  $\mu$ l) and 13 nmol of cryptate-maleimide in 50  $\mu$ l of water are added. After overnight coupling at 4°C, the mixture is purified on NAP10 (elution as above) and the oligonucleotide-cryptate conjugate is eluted in the exclusion volume (1 ml). The  
 5 absence of free cryptate is verified by analytical FPLC (HR10/30 column filled with Sepharose G25 (Pharmacia), elution with 10 mM phosphate buffer, pH 7).

The oligonucleotide-cryptate [TBP-Eu<sup>3+</sup>] of structure [bpy.bpy.bpy-Eu<sup>3+</sup>]-S-(CH<sub>2</sub>)<sub>6</sub>-p-d(TTT TTT TTT GGG GG<sup>AH</sup>CG)<sub>3</sub>, which has, close to the 3' end, an aminohexyl arm which allows this conjugate to be bonded to a biomolecule, is thus  
 10 obtained.

**EXAMPLE 10. Photophysical properties of an oligonucleotide-cryptate [TBP-Eu<sup>3+</sup>]) conjugate obtained according to example 9:**

15 A. Lifetime:

The lifetime is measured on a dilution, in water, of the cryptate-oligonucleotide conjugate obtained in example 9, using the protocol of example 3 (Method A).

It is observed that, in water or in the phosphate buffer, the main line  
 20 ( $\lambda_{\text{em}} = 620$  nm) has a lifetime of  $t_p = 1.33$  ms (Correlation Coefficient C.C = 0.999), this long lifetime is to be compared with the value of 1.1 ms (example 3A) obtained for the cryptate-oligonucleotide conjugate, the synthesis of which is described in example 2.

25 B. Quenching by uric acid:

The percentage quenching by uric acid is evaluated as described in example 4 so as to obtain final concentrations of 0, 2.5, 5, 10, 20, 40 and 80 mg/l of uric acid.

A reference sample of free cryptate is treated in the same way.

The results are given in table 3 below:

30

TABLE 3

Uric acid (mg/ml)	Free cryptate Quenching at 620 nm (%)	Conjugate of example 9 Quenching at 620 nm (%)
0	0	0
2.5	81	32
5	92	38
10	97	43
20	98	46
40	98	47
80	98	53

It is observed that the structure of the cryptate-oligonucleotide conjugate  
 5 confers a resistance to quenching by uric acid of the same order of that which was  
 observed for the conjugate of example 2.

Similarly, the measurement of the lifetime according to example 3A shows  
 that the main line ( $\lambda_{em} = 620 \text{ nm}$ ) has a lifetime in the phosphate buffer of  
 $t_s = 1.1 \text{ ms}$  (C.C = 0.99).

10 Consequently, the way in which the covalent bond between the cryptate  
 unit and the oligonucleotide is created does not have any substantial effect on the  
 photophysical properties of the conjugates.

**EXAMPLE 11. Coupling of a cryptate[bisdiethoxybpy.bpy-(Eu3+)]-maleimide  
 15 conjugate to a thiol-oligonucleotide:**

In this example, a cryptate made of two 4,4'-diethoxy-2,2'-bipyridine units  
 and of one 4,4'-di(methyl carboxylate)-2,2'-bipyridine unit is used. This cryptate is  
 synthesized according to the process described in application EP 0 321 353, by  
 20 condensation, in the presence of sodium carbonate in acetonitrile at reflux, of 2  
 equivalents of 6,6'-dibromomethyl-4,4'-diethoxy-2,2'-bipyridine and 1 equivalent of  
 6,6'-diaminomethyl-4,4'-di(methyl carboxylate)-2,2'-bipyridine derivative. The  
 cryptate [bisdiethoxybpy.diCOOCH<sub>3</sub>bpy]NaBr is thus obtained. This sodium cryptate  
 is then converted to europium cryptate [bisdiethoxybpy.diCOOCH<sub>3</sub>bpy-Eu<sup>3+</sup>] with  
 25 EuCl<sub>3</sub>.6H<sub>2</sub>O in methanol at reflux. This europium cryptate dimethyl ester is then

treated with ethylenediamine (4h at 20°C) and the resulting europium cryptate diamine [bisdiethoxybpy.(di-NH<sub>2</sub>(CH<sub>2</sub>)<sub>2</sub>-NHCO-bpy)-Eu<sup>3+</sup>] is purified by RP-HPLC.

This cryptate will be used as a reference cryptate and will be termed K'NH2 in example 12 below. It is then treated with SMP (Pierce) in order to introduce a maleimide group. A cryptate [bisdiethoxybpy.bipy-Eu<sup>3+</sup>]-maleimide conjugate is thus obtained. This cryptate-maleimide conjugate, purified on RP-HPLC, is coupled, according to the protocol of example 9, to the thiol-oligonucleotide ODN4 described in that example. An oligonucleotide-[bisdiethoxybpy.bipy-(Eu<sup>3+</sup>)] conjugate is thus obtained. The UV spectrum of this conjugate exhibits a maximum around 260 nm corresponding to the oligonucleotide and 2 shoulders around 305 nm and 337 nm corresponding to the cryptate component.

**EXAMPLE 12. Photophysical properties of the oligonucleotide-cryptate[bisdiethoxybpy.bipy-(Eu3+)] conjugate obtained according to example 11:**

The lifetime measurements for the oligonucleotide-cryptate [bisdiethoxybpy.bipy-(Eu3+)] conjugate (example 11) in the phosphate buffer are carried out according to the protocol described in the example and using, as a reference cryptate, the compound K'NH2 described in example 11.

The results are given in Table 4 below:

**TABLE 4**

Medium	Oligonucleotide-cryptate[bisdiethoxybpy.bipy-(Eu3+)] conjugate Lifetime (ms)	K'NH2 Lifetime (ms)
Phosphate	0.8	0.6
Phosphate + serum	0.8	0.2

It is observed, therefore, that the reference K'NH2 brought together with serum shows a phenomenon of quenching which causes a significant decrease in the lifetime in comparison with the value observed in the phosphate alone.

It is observed that the oligonucleotide-cryptate[bisdiethoxybpy.bpy-(Eu3+)] conjugate is not affected by the serum.

This example shows that the protective effect of the oligonucleotide component is independent of the structure of the cryptate.

CLAIMS

1. A process for reducing the fluorescence quenching caused by the measuring medium, in a fluorescence assay for an analyte using at least one  
5 fluorescent label, characterized in that a fluorescent conjugate comprising an oligonucleotide bonded to a rare-earth metal cryptate is introduced into the measuring medium.

2. The process as claimed in claim 1, characterized in that the oligonucleotide consists of a chain of ribonucleotide or deoxyribonucleotide units  
10 bonded to one another via phosphodiester-type bonds.

3. The process as claimed in claim 1, characterized in that the oligonucleotide consists of a chain of ribonucleotide or deoxyribonucleotide units or of analogous units of nucleotides modified on the sugar or on the base and bonded to one another via natural phosphodiester-type internucleotide bonds, some of the  
15 internucleotide bonds optionally being replaced with phosphonate, phosphoramidate or phosphorothioate bonds.

4. The process as claimed in claim 1, characterized in that the oligonucleotide consists of a chain comprising both ribonucleotide or deoxyribonucleotide units bonded to one another via phosphodiester-type bonds and analogous units of nucleosides bonded to one another via amide bonds.  
20

5. The process as claimed in any one of claims 1 to 4, characterized in that the oligonucleotide consists of ribonucleotide or deoxyribonucleotide units, one of which may comprise a functional group introduced onto or generated on said unit, or a functional group introduced using a spacer arm bonded to the terminal  
25 phosphate group in the 3' or 5' position.

6. The process as claimed in claim 5, characterized in that said unit is the 5' terminal unit or 3' terminal unit.

7. The process as claimed in any one of claims 1 to 6, characterized in that the oligonucleotide comprises a chain of 5 to 50 nucleotides or a chain of 5 to  
30 50 nucleotides and nucleotide or nucleoside analogs.


8. The process as claimed in any one of claims 1 to 6, characterized in that the oligonucleotide consists of a chain of ribonucleotide or deoxyribonucleotide units bonded to one another via phosphodiester-type bonds and of analogous units of nucleosides bonded to one another via amide bonds, said oligonucleotide



comprising at least 5 phosphodiester-type internucleotide bonds at the end intended to be bonded to the cryptate.

9. The process as claimed in any one of claims 1 to 8, characterized in that the rare-earth metal cryptate is bonded covalently to the oligonucleotide either directly or via a spacer arm.

10. The process as claimed in any one of claims 1 to 9, characterized in that said rare-earth metal cryptate consists of at least one rare-earth metal salt complexed with a macropolycyclic compound of formula



in which Z is an atom with 3 or 4 valencies, R is nothing or represents hydrogen, a hydroxy group, an amino group or a hydrocarbon-based radical, the divalent radicals  $\text{A}$ ,  $\text{B}$  and  $\text{C}$ , are, independently of each other, hydrocarbon-



based chains which optionally contain one or more hetero atoms and are optionally interrupted with a hetero macrocycle, at least one of the radicals  $\text{A}$ ,  $\text{B}$  and  $\text{C}$ , also comprising at least one molecular unit or consisting essentially of a molecular unit, said molecular unit having a triplet energy which is greater than that of the emission level of the complexed rare-earth metal ion.

11. The process as claimed in claim 10, characterized in that the rare-earth metal cryptate consists of a rare-earth metal salt complexed with one of the macrocyclic or macropolycyclic compounds below:

(22)phenanthroline; (22)phenanthrolineamide; (22)anthracene;  
(22)anthracenamide; (22)biisoquinoline; (22)biphenylbispyridine; (22)bipyridine;  
(22)bipyridinamide; the macropolycycles trisbipyridine, trisphenanthroline,  
phenanthrolinebisbipyridine, biisoquinolinebisbipyridine, bisbipyridine  
diphenylbipyridine; a macropolycyclic compound comprising a molecular unit


chosen from bipyrazines, bipyrimidines and nitrogen-containing heterocycles comprising N-oxide groups.

12. The process according to any one of claims 1 to 9, characterized in that the rare-earth metal cryptate consists of at least one rare-earth metal salt  
5 complexed with a macropolycyclic compound corresponding to one of the formulae II or III below:





in which:

- the ring of formula



is one of the following rings:



5

- Y is a spacer group or spacer arm which consists of a divalent organic radical, chosen from linear or branched  $C_1$  to  $C_{20}$  alkylene groups optionally containing one or more double bonds and/or optionally containing one or more hetero atoms such as oxygen, nitrogen, sulfur or phosphorus or one or more carbamoyl or carboxamido group(s); chosen from  $C_5$  to  $C_8$  cycloalkylene groups or chosen from  $C_6$  to  $C_{14}$  arylene groups, said alkylene, cycloalkylene or arylene groups being optionally substituted with alkyl, aryl or sulfonate groups;

- Z is a functional group capable of bonding covalently to a biological substance;



- R is a methyl group or represents the group -Y-Z;

- R' is hydrogen or a group -COOR'' in which R'' is a  $C_1$  to  $C_{10}$  alkyl group and preferably represents a methyl, ethyl or tert-butyl group, or alternatively R' is a group -CO-NH-Y-Z.

13. The process as claimed in any one of claims 1 to 12, characterized in that the rare-earth metal cryptate is bonded to the oligonucleotide via a spacer arm consisting of a divalent organic radical chosen from  $C_1$ - $C_{20}$  linear or branched alkylene groups optionally containing one or more double bonds or triple bonds

and/or optionally containing one or more hetero atoms, such as oxygen, nitrogen, sulfur, phosphorus or one or more carbamoyl or carboxamido group(s); C<sub>5</sub>-C<sub>8</sub> cycloalkylene groups and C<sub>6</sub>-C<sub>14</sub> arylene groups, said alkylene, cycloalkylene or arylene groups being optionally substituted with alkyl, aryl or sulfonate groups.

14. The process as claimed in claim 13, characterized in that the spacer arm is chosen from the groups:



in which  $n = 2$  to  $6$ , and  $\text{---CONH---(CH}_2\text{)}_6\text{---}$ , the attachment via the group  $\text{---CONH}$  taking place on the cryptate.

15. The method as claimed in any one of claims 1 to 14, characterized in that the rare-earth metal cryptate is a europium cryptate.

16. The process as claimed in claim 15, characterized in that the rare-earth metal cryptate is the europium cryptate Eu trisbipyridine or Eu [bisdiethoxybipyridine.bipyridine].

17. The process as claimed in any one of claims 1 to 16, characterized in that the fluorescent conjugate is used as the only label or as one of the fluorescent labels in the assay.

18. The process as claimed in any one of claims 1 to 17, characterized in that the fluorescent conjugate is bonded covalently to one of the members of a pair of molecules capable of binding specifically to one another, in particular a cellular receptor, an antigen, an antibody or a nucleic acid.


19. The process as claimed in any one of claims 1 to 18, characterized in that, in addition to said fluorescent conjugate, a fluorescent label comprising an acceptor fluorescent compound is used in the assay.

## ABSTRACT

- 5           The invention relates to a process for reducing the fluorescence quenching caused by the measuring medium, in a fluorescence assay for an analyte using at least one fluorescent label, characterized in that a fluorescent conjugate comprising an oligonucleotide bonded to a rare-earth metal cryptate is introduced into the measuring medium.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
2147  
2148  
2149  
2150  
2151  
2152  
2153  
2154  
2155  
2156  
2157  
2158  
2159  
2160  
2161  
2162  
2163  
2164  
2165  
2166  
2167  
2168  
2169  
2170  
2171  
2172  
2173  
2174  
2175  
2176  
2177  
2178  
2179  
2180  
2181  
2182  
2183  
2184  
2185  
2186  
2187  
2188  
2189  
2190  
2191  
2192  
2193  
2194  
2195  
2196  
2197  
2198  
2199  
2200  
2201  
2202  
2203  
2204  
2205  
2206  
2207  
2208  
2209  
2210  
2211  
2212  
2213  
2214  
2215  
2216  
2217  
2

Figure 1



Conjugate KH-ODN1

B = Adenine (A), Guanine (G), Cytosine (C), Thymine (T)

C = Cytosine

## COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY

(Includes Reference to PCT International Applications)

ATTORNEY'S DOCKET NUMBER

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Process for reducing the fluorescence quenching caused by the measuring medium

the specification of which (check only one item below):

☐ is attached hereto.

☐ was filed as United States application

Serial No. \_\_\_\_\_

on \_\_\_\_\_,

and was amended

on \_\_\_\_\_ (if applicable).

☒ was filed as PCT international application

Number PCT/FR00/00608

on March 14, 2000,

and was amended under PCT Article 19

on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

## PRIOR FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. 119:

COUNTRY (if PCT indicate PCT )	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 USC 119
France	99 03150	15/03/1999	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO

**Combined Declaration For Patent Application and Power of Attorney (Continued)**

ATTORNEY'S DOCKET NUMBER

(Includes Reference to PCT International Applications)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

U.S. APPLICATION NUMBER	U.S. FILING DATE	PATENTED	PENDING	ABANDONED

PCT APPLICATION NO.	PCT FILING DATE	U.S. SERIAL NUMBERS ASSIGNED (if any)			

**POWER OF ATTORNEY:** As a named inventor, I hereby appoint I. William Millen (19,544); John L. White (17,746); Anthony J. Zelano (27,969); Alan E. J. Branigan (20,565); John R. Moses (24,983); Harry B. Shubin (32,004); Brion P. Heaney (32,542); Diana Hamlet-King (33,302); Richard J. Traverso (30,595); Richard E. Kurtz (33,936) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Send Correspondence to: **MILLEN, WHITE, ZELANO AND BRANIGAN, P.C.** Telephone No. Direct Telephone Calls to:

**Arlington Courthouse Plaza I, Suite 1201**  
**2200 Clarendon Boulevard**  
**Arlington, Virginia 22201**

**703-243-6333**

**Direct Telephone Calls to:**

201	FULL NAME OF INVENTOR	FAMILY NAME <u>MATHIS</u>	FIRST GIVEN NAME <u>Gérard</u>	SECOND GIVEN NAME
	RESIDENCE & CITIZENSHIP	CITY <u>Bagnols sur Cèze</u> <u>FR</u>	STATE OR FOREIGN COUNTRY <u>France</u>	COUNTRY OF CITIZENSHIP <u>France</u>
	POST OFFICE ADDRESS	STREET <u>17 Impasse Capelle</u> <u>des Ladres</u>	CITY <u>Bagnols sur Cèze</u>	STATE & ZIP CODE/COUNTRY <u>30200 - France</u>
202	FULL NAME OF INVENTOR	FAMILY NAME <u>BAZIN</u>	FIRST GIVEN NAME <u>Hervé</u>	SECOND GIVEN NAME
	RESIDENCE & CITIZENSHIP	CITY <u>Villeneuve les Avignon</u> <u>FR</u>	STATE OR FOREIGN COUNTRY <u>France</u>	COUNTRY OF CITIZENSHIP <u>France</u>
	POST OFFICE ADDRESS	STREET <u>14 Allée de la</u> <u>Chenaie</u>	CITY <u>Villeneuve les Avignon</u>	STATE & ZIP CODE/COUNTRY <u>30400 - France</u>
203	FULL NAME OF INVENTOR	FAMILY NAME <u>TRINQUET</u>	FIRST GIVEN NAME <u>Eric</u>	SECOND GIVEN NAME
	RESIDENCE & CITIZENSHIP	CITY <u>Pont Saint Esprit</u> <u>FR</u>	STATE OR FOREIGN COUNTRY <u>France</u>	COUNTRY OF CITIZENSHIP <u>France</u>
	POST OFFICE ADDRESS	STREET <u>Chemin Columbia</u>	CITY <u>Pont Saint Esprit</u>	STATE & ZIP CODE/COUNTRY <u>30130 - France</u>
204	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	STREET	CITY	STATE & ZIP CODE/COUNTRY
205	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	STREET	CITY	STATE & ZIP CODE/COUNTRY
206	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	STREET	CITY	STATE & ZIP CODE/COUNTRY



# Combined Declaration For Patent Application and Power of Attorney (Continued)

(Includes Reference to PCT International Applications)

ATTORNEY'S DOCKET NUMBER

207	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	STREET	CITY	STATE & ZIP CODE/COUNTRY
208	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	STREET	CITY	STATE & ZIP CODE/COUNTRY
209	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	STREET	CITY	STATE & ZIP CODE/COUNTRY
210	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	STREET	CITY	STATE & ZIP CODE/COUNTRY
211	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	STREET	CITY	STATE & ZIP CODE/COUNTRY
212	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	STREET	CITY	STATE & ZIP CODE/COUNTRY

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

SIGNATURE OF INVENTOR 207 <i>G. Babin</i>	DATE August 24, 2001	SIGNATURE OF INVENTOR 207	DATE
SIGNATURE OF INVENTOR 208 <i>H. Babin</i>	DATE August 24, 2001	SIGNATURE OF INVENTOR 208	DATE
SIGNATURE OF INVENTOR 209 <i>E. TRINQUET</i>	DATE August 24, 2001	SIGNATURE OF INVENTOR 209	DATE
SIGNATURE OF INVENTOR 204	DATE	SIGNATURE OF INVENTOR 210	DATE
SIGNATURE OF INVENTOR 205	DATE	SIGNATURE OF INVENTOR 211	DATE
SIGNATURE OF INVENTOR 206	DATE	SIGNATURE OF INVENTOR 212	DATE